The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism

[1]  Carlo Colosimo,et al.  Multiple system atrophy , 2004, The Lancet Neurology.

[2]  W. Oertel,et al.  Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography , 1997, European Journal of Nuclear Medicine.

[3]  Markus Piel,et al.  Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Y. Fukuuchi,et al.  [SPECT imaging using [123I]beta-CIT and [123I]IBF in extrapyramidal diseases]. , 2003, No to shinkei = Brain and nerve.

[5]  B. Christian,et al.  Brain imaging of 18F‐fallypride in normal volunteers: Blood analysis, distribution, test‐retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D‐2/D‐3 receptors , 2002, Synapse.

[6]  W. Heiss,et al.  Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging , 2002, Journal of neurology, neurosurgery, and psychiatry.

[7]  Markus Piel,et al.  Quantification of D 2-Like Dopamine Receptors in the Human Brain with 18 F-Desmethoxyfallypride , 2002 .

[8]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[9]  S. Asenbaum,et al.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease , 2000, Journal of Neurology.

[10]  V Kaasinen,et al.  Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  I Litvan,et al.  Recent advances in atypical parkinsonian disorders. , 1999, Current opinion in neurology.

[12]  C. Adler.  Differential diagnosis of Parkinson's disease. , 1999, The Medical clinics of North America.

[13]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[14]  W. Oertel,et al.  123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[15]  R P Maguire,et al.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. , 1997, Brain : a journal of neurology.

[16]  J. Jankovic,et al.  Decreased [18F]Spiperone Binding in Putamen in Idiopathic Focal Dystonia , 1997, The Journal of Neuroscience.

[17]  E. Wolters,et al.  IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. , 1997, Journal of neural transmission. Supplementum.

[18]  I Litvan,et al.  Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. , 1997, Brain : a journal of neurology.

[19]  J. Mukherjee,et al.  18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. , 1996, Life sciences.

[20]  J. Foster.  BOOK REVIEWS , 1993 .

[21]  A. Churchyard,et al.  Dopa resistance in multiple‐system atrophy: Loss of postsynaptic D2 receptors , 1993, Annals of neurology.

[22]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.

[23]  L. Wilkins.  123 1-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.

[24]  T. Gasser,et al.  123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.

[25]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[26]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[27]  J. Perlmutter,et al.  Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  A. Alavi,et al.  In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  R. Beck,et al.  Dopamine D-2 receptors imaged by PET in Cebus apella using [18F]benzamide neuroleptic. , 1990, European journal of pharmacology.

[30]  N. Quinn,et al.  Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[31]  A. Alavi,et al.  In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[33]  J. Swets.  ROC analysis applied to the evaluation of medical imaging techniques. , 1979, Investigative radiology.